PI Form 4: Chris Diorio Disposes 10,000 Shares in August 2025

Rhea-AI Filing Summary

Insider Form 4 — Impinj, Inc. (PI) Dr. Chris Diorio, CEO and Director, reported preplanned sales under a Rule 10b5-1 trading plan effective May 28, 2025. The filing discloses a total of 10,000 shares sold across transactions on August 28–29, 2025, in multiple tranches with reported weighted-average prices by tranche ranging approximately from $185.93 to $190.79. After these disposals Dr. Diorio directly beneficially owned 356,109 shares and indirectly owned 199,362 shares through DFT L.L.C. The filing includes explanations that sales were executed pursuant to the 10b5-1 plan and provides price ranges for the individual tranches.

Positive

• None.

Negative

• CEO sold 10,000 shares in August 2025, reducing direct holdings to 356,109 shares.
• Sales were material in aggregate (10,000 shares) and occurred over two days, which some investors may view as notable.

Insights

Corporate Governance Expert

TL;DR: CEO sold 10,000 shares under a 10b5-1 plan, indicating preplanned dispositions rather than ad-hoc selling.

The sales are explicitly described as executed pursuant to a Rule 10b5-1 trading plan effective May 28, 2025. Use of a pre-established plan generally reduces the likelihood that these transactions reflect contemporaneous, undisclosed company information. The filing discloses tranche-level weighted-average prices and cumulative quantities, which increases transparency. From a governance perspective, documentation of the 10b5-1 plan and clear tranche reporting align with good disclosure practice.

Securities Analyst

TL;DR: CEO sales totaled 10,000 shares at prices ~ $185.34–$190.93, modest in scale relative to typical institutional holdings.

The filing details nine disposals over two days with weighted-average prices reported by tranche and explicit ranges for individual execution prices. The director remains a substantial shareholder directly (356,109 shares) and indirectly (199,362 shares), so these sales represent a reduction but not a full exit. Because transactions were under a 10b5-1 plan, immediate market-impact interpretation is limited; the disclosure allows investors to verify quantities and price bands if desired.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DIORIO CHRIS PH.D.

(Last) (First) (Middle)

400 FAIRVIEW AVENUE NORTH

SUITE 1200

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IMPINJ INC [ PI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2025		S(1)		1,112	D	$185.9255(2)	364,997	D
Common Stock	08/28/2025		S(1)		784	D	$186.7989(3)	364,213	D
Common Stock	08/28/2025		S(1)		1,749	D	$188.1404(4)	362,464	D
Common Stock	08/28/2025		S(1)		960	D	$189.0634(5)	361,504	D
Common Stock	08/28/2025		S(1)		325	D	$190.3271(6)	361,179	D
Common Stock	08/28/2025		S(1)		70	D	$190.7886(7)	361,109	D
Common Stock	08/29/2025		S(1)		2,000	D	$188.3865(8)	359,109	D
Common Stock	08/29/2025		S(1)		2,800	D	$189.3862(9)	356,309	D
Common Stock	08/29/2025		S(1)		200	D	$190.28	356,109	D
Common Stock								199,362	I	by DFT L.L.C.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $185.34.00 to $186.32, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

3. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $186.43 to $187.305, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

4. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $187.5801 to $188.57 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

5. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.585 to $189.335, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

6. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $189.70 to $190.675, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

7. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.75 to $190.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

8. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.00.00 to $188.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein

9. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $189.10 to $189.74, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

	/s/ Yukio Morikubo, Attorney in fact for Chris Diorio	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Impinj (PI) disclose on the Form 4?

The Form 4 reports that CEO and Director Chris Diorio sold 10,000 shares on August 28–29, 2025, under a Rule 10b5-1 plan.

Were the sales by Chris Diorio preplanned or ad hoc?

The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan effective May 28, 2025, indicating preplanned dispositions.

How many shares does the reporting person own after the transactions?

After the reported transactions, Dr. Diorio directly beneficially owned 356,109 shares and indirectly owned 199,362 shares through DFT L.L.C.

What price range did the reported sales occur at?

The filing discloses tranche price ranges and weighted-average prices; individual execution prices ranged approximately from $185.34 to $190.93 across the reported tranches.

Who signed the Form 4 on behalf of Chris Diorio?

The Form 4 was signed by Yukio Morikubo, Attorney in fact for Chris Diorio on 08/29/2025.